Market closed

Zymeworks/$ZYME

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Ticker

$ZYME
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Middletown, United States

Employees

294
Website
www.zymeworks.com

Zymeworks Metrics

BasicAdvanced
$938M
-
-$1.52
1.10
-

$938M

1.1

$17.11

$7.97

525K

4.097

3.824

4.716

5.526

-14.69%

-28.73%

16.398

2.58

2.72

-17.262

-86.52%

-150.18%

40.37%

-30.10%

What the Analysts think about Zymeworks

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.

Zymeworks Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zymeworks Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Zymeworks News

AllArticlesVideos
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

GlobeNewsWire·6 days ago
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Seeking Alpha·4 weeks ago
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZYME

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Zymeworks stock?

Zymeworks (ZYME) has a market cap of $938M as of January 15, 2025.

What is the P/E ratio for Zymeworks stock?

The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of January 15, 2025.

Does Zymeworks stock pay dividends?

No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Zymeworks dividend payment date?

Zymeworks (ZYME) stock does not pay dividends to its shareholders.

What is the beta indicator for Zymeworks?

Zymeworks (ZYME) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.